# NewLimit raises $435M Series C to take its liver reprogramming medicine toward human trials

Canonical page: https://technooptimist.io/stories/newlimit-raises-435m-series-c-to-take-its-liver-reprogramming-medicine-870dee26
Date: 2 Jun 2026
About: [NewLimit](https://technooptimist.io/companies/newlimit.md) · [Hepatocyte epigenetic reprogramming](https://technooptimist.io/longevity/hepatocyte-reprogramming.md)
Original source: https://blog.newlimit.com/p/newlimit-raises-435m-led-by-founders

NewLimit closed a $435 million Series C led by Founders Fund. The company says the round brings its first aging reprogramming medicine, a liver therapy, to human clinical trials next year.

## Key facts

- $435M Series C led by Founders Fund; new investors include Thrive Capital, Greenoaks and Quiet Capital; returning investors include Kleiner Perkins and Eli Lilly Ventures.
- The company had earlier expected trials to take more than a decade; it now cites an accelerated timeline based on a prototype that reverses cell age in old human liver cells.
- The therapy is an mRNA payload delivered in lipid nanoparticles, aimed at helping livers heal faster after injury.
- The company has not announced manufacturing milestones in this post.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.